• Title/Summary/Keyword: Cancer Patient

Search Result 3,942, Processing Time 0.031 seconds

Recurrence Season Impacts the Survival of Epithelial Ovarian Cancer Patients

  • Liu, Xiao-Hui;Man, Ya-Nan;Wu, Xiong-Zhi
    • Asian Pacific Journal of Cancer Prevention
    • /
    • v.15 no.4
    • /
    • pp.1627-1632
    • /
    • 2014
  • Background: Several studies indicated that the diagnosis season affects the prognosis of some cancers, such as examples in the prostate, colon and breast. This retrospective study aimed to investigate whether the diagnosis and recurrent season impacts the prognosis of epithelial ovarian cancer patients. Methods: From January 2005 to August 2010, 161 epithelial ovarian cancer patients were analyzed and followed up until August 2013. Kaplan-Meier survival curves and the log-rank test were used to make the survival analysis. Multivariate analysis was conducted to identify independent prognostic factors. Results: The prognostic factors of overall survival in epithelial ovarian cancer patients included age, clinical stage, pathological type, histological grade, residual disease after primary surgery, recurrent season and adjuvant chemotherapy cycles. Moreover, clinical stage, histological grade, residual disease after primary surgery, recurrent season and adjuvant chemotherapy cycles also impacted the progression-free survival of epithelial ovarian cancer patients. The diagnosis season did not have a significantly relationship with the survival of operable epithelial ovarian cancer patients. Median overall survival of patients with recurrent month from April to November was 47 months, which was longer (P < 0.001) than that of patients with recurrence month from December to March (19 months). Median progression-free survival of patients with recurrence month from April to November and December to March was 20 and 8 months, respectively (P < 0.001). Conclusion: The recurrence season impacts the survival of epithelial ovarian cancer patients. However, the diagnosed season does not appear to exert a significant influence.

A case report of a clinically diagnosed advanced lung cancer patient after treatment with Gunchilgyebok-Jung (건칠계복정으로 치료한 임상적 진행성 폐암 환자 1례)

  • Park, So jung;Kang, Hwi joong;Park, Ji hye;Cho, Chong kwan;Yoo, Hwa seung
    • Journal of Korean Traditional Oncology
    • /
    • v.20 no.1
    • /
    • pp.23-29
    • /
    • 2015
  • Objective : This case report presents the effects of Gunchilgyebok-Jung to a patient who was clinically diagnosed with advanced lung cancer. Methods : The study involved a 74-year-old male patient clinically diagnosed with advanced (stage III) lung cancer by chest computed tomography (CT) and positron emission tomography. The patient had two masses (11.32 mm and $23.03mm{\times}35.34mm$) in the right upper lobe of the lung and in the mediastinum respectively. Gunchilgyebok-Jung commonly used for its anti-tumor and anti-inflammatory effect is composed of Rhus verniciflua stokes and Guizhifuling wan extracts. We prescribed Gunchilgyebok-Jung at a dosage of 1 g three times a day for 50 days. Results : After the administration of Gunchilgyebok-Jung, a decrease in tumor size to 10.69 mm and $22.71mm{\times}34.21mm$ on chest CT was observed. A numerical rating scale (NRS) showed an improvement in symptoms from points 7-8 to 3-4. Conclusion : This study suggests that Gunchilgyebok-Jung may have considerable anti-tumor and immunopotentiating activity in lung cancer without any adverse effects.

A Case Report of a Patient with Advanced Non-Small Cell Lung Cancer Treated with Allergen Removed Rhus Verniciflua Stokes (aRVS) (알러젠 제거 옻나무 추출물 투여로 생존기간이 연장된 4기 비소세포성폐암 환자 1례)

  • Choi, Seong-Heon;Song, An-Na;An, Ji-Hye;Kim, Eun-Hee;Park, So-Jeong;Lee, Soo-Kyung;Kim, Kyung-Suk
    • Journal of Korean Traditional Oncology
    • /
    • v.17 no.1
    • /
    • pp.45-53
    • /
    • 2012
  • Objective : We introduce a case of non-small cell lung cancer patient treated with allergen removed Rhus verniciflua Stokes. Methods : This patient started Allergen-removed Rhus Verniciflua Stokes from Feb 2010 right after his firstline chemotherapy, and maintained his Oriental medicine regimen until now. Results : It shows 12.0 months of progression-free-survival since starting point of maintenance chemotherapy, and 9.3 months of overall-survival since progression disease after 2nd chemotherapy, compared with 6.3 months of its known overall survival. Conclusion : Allergen removed Rhus verniciflua Stokes prolonged overall survival and slowed disease progression of a non-small cell lung cancer patient.

Delayed Presentation of Self-discovered Breast Cancer Symptoms in Iranian Women: A Qualitative Study

  • Khakbazan, Zohreh;Taghipour, Ali;Roudsari, Robab Latifnejad;Mohammadi, Eesa;Omranipour, Ramesh
    • Asian Pacific Journal of Cancer Prevention
    • /
    • v.15 no.21
    • /
    • pp.9427-9432
    • /
    • 2014
  • Background: Delayed presentation of symptomatic breast cancer is a public health issue in Iran, making a major contribution to low survival. Despite the importance of this problem, current knowledge is insufficient to inform interventions to shorten patient delay. The aim of this study was to explore factors influencing patient delay in Iranian women with self-discovered breast cancer symptom. Materials and Methods: This qualitative study was conducted during 2012-2013. Purposeful sampling was used to recruit 20 Iranian women with self-discovered symptoms of breast cancer who attended the Cancer Institute of Tehran University of Medical Sciences, Tehran, Iran. Data were collected through semi-structured in-depth audiotaped interviews, which were transcribed and analyzed using conventional content analysis with MAXqda software version 10. Findings: Content analysis of the data revealed four main themes related to the delay in seeking medical help including: 1) attributing symptoms to the benign conditions; 2) conditional health behavior; 3) inhibiting emotional expression; and 4) barriers to access to health care systems. Conclusions: These results suggest that patient delay is influenced by complex and multiple factors. Effective intervention to reduce patient delay for breast cancer should be developed by focusing on improvement of women's medical knowledge, managing patients' emotional expression and reform of the referral system.

Case Study of a Breast Cancer Patient Accompanying with Hot Flush by Tamoxifen Whose Condition Was Improved by Jayeumganghwa-tang (자음강화탕 투여 후 상열감의 호전을 보인 타목시펜 복용 중인 유방암 환자 1례)

  • Zheng, Hong-Mei;Lee, Yeon-Weol;Yoo, Hwa-Seung;Cho, Chong-Kwan
    • The Journal of Internal Korean Medicine
    • /
    • v.31 no.2
    • /
    • pp.395-400
    • /
    • 2010
  • Objective : To observe the effectiveness of Jayeumganghwa-tang on hot flush of a breast cancer patient who takes tamoxifen. Methods : For six weeks a dosage witch contained 13.92g of Jayeumganghwa-tang was administered 3 times (30 mins after meal) per day, for improvement of hot flush. No other therapies like hormone therapy or substituted therapy were done. Results : As a result of 6 weeks of Jayeumganghwa-tang therapy, the patient who suffered hot flush on taking tamoxifen showed improvement on several indices, including frequency, intensity and point of hot flush, Beck Depression Inventory-K (BDI-K) which shows uneasiness and sadness, and also Functional Assessment Cancer Therapy - Breast (FACT-B) which is an index of life quality of breast cancer patients. But no changes on female hormones like follicle-stimulating hormone (FSH) or luteinizing hormone (LH) were observed. Conclusion : This case demonstrates 6 weeks of Jayeumganghwa-tang taking had no effect on female hormones but can reduce the hot flush by tamoxifen. This shows minimum evidence of safety and efficacy of Jayeumganghwa-tang on hot flush of breast cancer patient. However this is a single case study so further case-series research should be compiled.

Case Report of Terminal Cancer Patient by Community Health Practitioner (보건진료소에서의 말기 암 환자 간호사례)

  • Jeong, Migyung
    • Journal of Korean Academy of Rural Health Nursing
    • /
    • v.15 no.1
    • /
    • pp.30-40
    • /
    • 2020
  • Purpose: This study was done to describe a community health practitioner's nursing case management for a terminal cancer patient registered in the public health post. Methods: For this purpose, data were collected through the patient and family through home visits, health clinic offices, and phone calls. The nursing process was carried out from August to November 2019. Results: The patient suffered the most from anorexia and lack of energy. Also he expressed psychologically uncertainty about disease and death anxiety caused by long-term treatment. In order to reduce the death anxiety, Community Health Practitioner (CHP) asked him to express his life stories and listened to him. CHP provided information of appropriate medications and alternative foods for symptoms such as gastrointestinal disorders and anorexia to the patient and family. Observing the situation of the patient and family, CHP guided the patient and family to prepare for death and has confirmed to them that the process was not with the patient alone. Conclusion: CHP's this experience has shown the possibility for CHP to help the terminal cancer patient and family to prepare peaceful death in their communities.

The Impact of Time-to-Treatment for Outcome in Cancer Patients, and Its Differences by Region and Time Trend (암환자의 진단-치료 소요기간에 따른 생존분석과 지역사회별 격차 및 시계열적 추이)

  • Kim, Woorim;Han, Kyu-Tae
    • Health Policy and Management
    • /
    • v.31 no.1
    • /
    • pp.91-99
    • /
    • 2021
  • Background: The Korean government introduced National Cancer Control Program and strengthening national health insurance coverage for cancer patients. Although many positive effects have been observed, there are also many concerns about cancer management such as patient concentration or time-to-treatment. Thus, we investigated the association between the time-to-treatment and survival of cancer patients, and compared regional differences by time trend. Methods: The data used in this study were national health insurance claims data that included patients diagnosed with lung cancer and received surgical treatment between 2005 and 2015. We conducted survival analysis with Cox proportional hazard model for the association between time-to-treatment and survival in lung cancer. Additionally, we compared the regional differences for time-to-treatment by time trend. Results: A total of 842 lung cancer patients were included, and 52.3% of lung cancer patients received surgical treatment within 30 days. Patients who received surgical treatment after 31 days had higher 5-year or 1-year mortality compared to treatment within 30 days (5-year: hazard ratio [HR], 1.566; 1-year: HR, 1.555; p<0.05). There were some regional differences for time-to-treatment, but it was generally reduced after 2010. Conclusion: Delayed surgical treatment after diagnosis can negatively affect patient outcomes in cancer treatment. To improve cancer control strategies, there are needed to analyze the healthcare delivery system for cancer care considering the severity and types of cancer.

A Correlation of Interleukin-6 of Pancreatic Cancer Patients and Cancer Progression: Case Series (췌장암 환자의 IL-6 수치와 암 진행의 상관 관계에 대한 3례 증례보고)

  • Han-eum Joo;Young-min Cho;Jun-yeol Kim;Jung-hyang Park;Soo-jin Kim;Hae-chang Yoon;Jung-hyo Cho
    • The Journal of Internal Korean Medicine
    • /
    • v.45 no.3
    • /
    • pp.508-518
    • /
    • 2024
  • Objectives: To report a correlation of IL-6 of pancreatic cancer and cancer progression in three pancreatic cancer patients. Method: Three pancreatic cancer patients were monitored for changes in IL-6 levels, tumor markers (CEA, CA19-9), and clinical outcomes over their treatment period. Results: Patient 1's IL-6 levels rose with liver metastasis and tumor progression, coinciding with increases in tumor markers. Patient 2's IL-6 levels remained elevated during chemotherapy, correlating with tumor growth. Patient 3's IL-6 levels spiked prior to cancer progression. Conclusion: Elevated IL-6 levels were observed in advancing pancreatic cancer patients, suggesting IL-6 as a potential biomarker for monitoring cancer progression in pancreatic cancer. Regular IL-6 monitoring could improve prognostic evaluations and treatment strategies.

A Case of Thyroid Papillary Cancer with Spinal Metastasis (유두상 갑상선 암의 척추전이 1예)

  • Yang, Suk Min;Chang, Jae Won;Shin, Yoo Seob;Kim, Chul-Ho
    • Korean Journal of Head & Neck Oncology
    • /
    • v.29 no.2
    • /
    • pp.79-82
    • /
    • 2013
  • Thyroid cancer is known as its relatively high cure rate after surgical treatment and spinal metastasis of thyroid cancer is extremely rare as the prevalence is only 2-13%. Spinal metastasis is usually asymptomatic and discovered incidentally in most cases. A 66-year-old man was diagnosed as thyroid papillary cancer with spinal metastasis. We treated the patient by surgery, adjuvant radiotheraphy and radioactive iodine therapy. C6 corpectomy was followed for the residual spinal metastasis by the department of neurosurgery. The patient had no functional complication by the surgical process. At 24 months after surgery, there was no sign of recurrence and the patient led social life without any discomfort. We present this case with a review of the related literatures.

Delayed radiation-induced inflammation accompanying a marked carbohydrate antigen 19-9 elevation in a patient with resected pancreatic cancer

  • Mattes, Malcolm D.;Cardinal, Jon S.;Jacobson, Geraldine M.
    • Radiation Oncology Journal
    • /
    • v.34 no.2
    • /
    • pp.156-159
    • /
    • 2016
  • Although carbohydrate antigen (CA) 19-9 is a useful tumor marker for pancreatic cancer, it can also become elevated from a variety of benign and malignant conditions. Herein we describe an unusual presentation of elevated CA 19-9 in an asymptomatic patient who had previously undergone adjuvant chemotherapy and radiation therapy for resected early stage pancreatic cancer. The rise in CA 19-9 might be due to delayed radiation-induced inflammation related to previous intra-abdominal radiation therapy with or without radiation recall induced by gemcitabine. After treatment with corticosteroids the CA 19-9 level decreased to normal, and the patient has not developed any evidence of recurrent cancer to date.